112 results on '"Borchmann, Sven"'
Search Results
2. Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA
3. Clinical applications of circulating tumor DNA in Hodgkin lymphoma
4. Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma
5. In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin’s lymphoma and facilitates ultrasensitive residual disease detection
6. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1
7. Human leukocyte antigen (HLA) class I expression on Hodgkin–Reed–Sternberg cells is an EBV‐independent major determinant of microenvironment composition in classic Hodgkin lymphoma.
8. Noninvasive minimal residual disease assessment in relapsed/refractory large B‐cell lymphoma using digital droplet PCR.
9. MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I
10. An atlas of the tissue and blood metagenome in cancer reveals novel links between bacteria, viruses and cancer
11. Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)
12. Hodgkin lymphoma in elderly patients
13. The genetics of Hodgkin lymphoma: an overview and clinical implications
14. Multi-Specific Antibodies for Cancer Immunotherapy
15. JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO).
16. EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer.
17. The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma
18. Reinduction therapy with everolimus in combination with dexamethasone, high‐dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD‐R3i)
19. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.
20. Noninvasive, Dynamic Risk Profiling of Primary Central Nervous System Lymphoma By Peripheral Blood Ctdna-Sequencing
21. Combining anti-VEGF-A and anti-PD-L1 therapy prolongs overall survival in small cell lung carcinomas
22. Coming of age: the evolving role of circulating tumor DNA in malignant lymphoma.
23. P1384: MULTI‐EFFECTOR IMMUNE CELL RETARGETING USING A BISPECIFIC SINGLE‐CHAIN VARIABLE FRAGMENT LIBRARY IN AGGRESSIVE B CELL LYMPHOMAS.
24. Steering Chimeric Antigen Receptor T Cells Into the Hodgkin Lymphoma Niche.
25. An update on disease biomarkers for Hodgkin lymphoma.
26. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials
27. Pretreatment Vitamin D Deficiency Is Associated With Impaired Progression-Free and Overall Survival in Hodgkin Lymphoma.
28. Throly Score Successfully Classifies Hodgkin Lymphoma Patients at Risk of Thromboembolic Complication
29. The translational science of hodgkin lymphoma.
30. P1209: PERIPHERAL BLOOD CTDNA-SEQUENCING ENABLES PREDICTION OF OUTCOMES IN PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA USING A DYNAMIC RISK MODEL.
31. P037: High breadth whole exome sequencing of circulating tumor DNA identifies novel recurrent genetic alterations in Hodgkin lymphoma.
32. Leucocyte and eosinophil counts predict progression‐free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition.
33. Novel agents in classical Hodgkin lymphoma.
34. Active Surveillance for Newly Diagnosed Nodular Lymphocyte-Predominant Hodgkin Lymphoma
35. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
36. Thrombosis in Hodgkin Lymphoma Patients: Incidence, Time Points, Risk Factors and Impact of Stage and Treatment
37. Seasonal Differences in Incidence and Survival of Hodgkin Lymphoma Depend on Geographic Location of Diagnosis
38. Suicide in European Hodgkin Lymphoma Patients
39. P059: Multi‐effector cell targeting with half‐life extended bispecific scFv in Hodgkin lymphoma.
40. P046: Preclinical evaluation of novel repurposed drug combinations in Hodgkin lymphoma.
41. Current developments in the treatment of early-stage classical Hodgkin lymphoma.
42. Blood‐based Monitoring of Relapsed/Refractory Hodgkin Lymphoma Patients Predict Responses to Anti‐PD‐1 Treatment.
43. Controversies in the Interpretation of Liquid Biopsy Data in Lymphoma.
44. Hodgkin Lymphoma—Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients.
45. Liquid biopsy in lymphoma: Molecular methods and clinical applications.
46. Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC.
47. Blocking the angiopoietin-2-dependent integrin β-1 signaling axis abrogates small cell lung cancer invasion and metastasis.
48. Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma.
49. Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors.
50. Liquid biopsy in Hodgkin lymphoma - moving beyond the proof of principle.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.